ALX Oncology Holdings (ALXO)
(Delayed Data from NSDQ)
$1.09 USD
+0.04 (3.81%)
Updated Sep 18, 2025 04:00 PM ET
After-Market: $1.20 +0.11 (10.09%) 7:58 PM ET
3-Hold of 5 3
D Value B Growth A Momentum B VGM
Fundamental Charts
About Return on Equity (TTM)
ALX Oncology Holdings Inc.'s return on equity, or ROE, is -115.67% compared to the ROE of the Medical - Biomedical and Genetics industry of -67.20%. While this shows that ALXO has struggled to make solid use of its equity, this metric will vary significantly from industry to industry.
Return on Equity (or ROE) is calculated as income divided by average shareholder equity (past 12 months, including reinvested earnings). The income number is listed on a company's Income Statement. Shareholder Equity (which is the difference between Total Assets and Total Liabilities) can be found on the Balance Sheet.
ALXO 1.09 +0.04(3.81%)
Will ALXO be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for ALXO based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ALXO
ALX Oncology Holdings (ALXO) Could Find a Support Soon, Here's Why You Should Buy the Stock Now
Is ALX Oncology Holdings (ALXO) Outperforming Other Medical Stocks This Year?
ALXO: What are Zacks experts saying now?
Zacks Private Portfolio Services
ALX Oncology Holdings (ALXO) Loses -27.11% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Other News for ALXO
ALX Oncology CEO Makes Bold Stock Purchase!
20 Day Moving Average Resistance appears for ALXO after 2.78% move
Insider Buying: Jason Lettmann Acquires 92,233 Shares of ALX Oncology Holdings Inc (ALXO)
12 Health Care Stocks Moving In Thursday's After-Market Session
Is ALXO positioned for a breakout? Boomer Buy Setup shows up after gaining 2.86%